As large multi-cancer datasets become more important for predicting who may benefit from cancer drugs, a new approach better accounts for potentially overlooked variation.

Targeting this inside-the-cell checkpoint could potentially improve response to cancer immunotherapy.

Engineers and oncologists teamed to develop a microfluidic chip capable of capturing the body’s natural killer immune cells to harvest their cancer-killing exosomes.

A new understanding of intracellular pathways activated as T cells start to mount an immune response offers clues against graft-versus-host disease, a serious complication of bone marrow transplantation.

The liver siphons critical immune cells to render immunotherapy ineffective; radiation to the liver may block this process.

Throughout the pandemic, researchers have continued to push the boundaries of cancer prevention, diagnosis and treatment.